


# Financial Tear Sheet

## Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

#### **Stock Information**

EBS (Common Stock)		
Exchange	NYSE (US Dollar)	
Price	\$35.02	
Change (%)	<b>▼</b> 0.47 (1.32%)	
Volume	103,099	
52 Week Low	\$24.47	
Market Cap	\$1,462,598,513	
Rolling EPS	1.39	
PE Ratio	25.4968	
Shares Outstanding	41,211,567	



Data as of 08/18/17 12:36 p.m. ET

#### Recent Headlines & Events

08/03/17

Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance

07/31/17

Emergent BioSolutions Awarded \$23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense

07/26/17

Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva's Zika Vaccine Technology

Date	Title
08/31/17 3:10 p.m. ET	Emergent BioSolutions Inc. at Three Part Advisors 2017 Midwest IDEAS Investor Conference

### **SEC Filings**

Filing Date	Form
08/17/17	4
08/14/17	CT ORDER
08/14/17	CT ORDER
08/10/17	4

Data provided by Nasdaq. Minimum 15 minutes delayed.

### **Primary IR Contact**

Robert G. Burrows Vice President, Investor Relations Emergent BioSolutions Inc.

**Phone:** (240) 631 3280 **Fax:** (240) 413-1917

E-mail: burrowsr@ebsi.com